Refreshing Medicine, Today
Exopharm (ASX: EX1) is a clinical stage company at the forefront of developing transformative medicines based upon exosomes (EVs). Our mission is to be a global leader in EV-based therapeutics.
Leaders in the development of transformative EV-based medicines
Exopharm is developing and commercialising EVs as therapeutics –
Engineered EVs (EEVs) as delivery vehicles for active cargo drugs to treat infectious diseases, neurological diseases and cancer; and
Naïve EVs (NEVs) from stem cells and platelets to treat selected conditions such as osteoarthritis and chronic and acute injuries
Partner with Exopharm to meet your EV medicine goals
- Solve delivery problems with existing ‘stranded assets’
- Target loaded drugs to specific cell types (i.e. confer tropism)
- Deliver drugs across biological barriers, including the blood brain barrier
EVs (also known as exosomes) harness the powerful natural ability of EVs to efficiently target cells and transfer selected materials into cells and across barriers. These natural yet powerful properties of EVs are now seen as a better way to deliver nucleic acid and other medicines.
Exopharm is advancing EV medicines in two main areas: engineered EVs as tools to deliver active drugs as precision medicines, and naïve EVs, or unaltered EVs, from stem cells and other cells as regenerative medicines.
Exopharm’s LEAP manufacturing technology provides access to large quantities of high-purity EVs for research and clinical uses.
Exopharm is a publicly traded company on the Australian Securities Exchange under code ASX:EX1.
Visit our Resources section for ASX announcements, investor information, news and articles.
Under News and Articles, access more information about EVs, news, whitepapers and opinion articles. Also find links to past talks and webinars.
An experienced and dedicated team
Founded in 2013 by Dr Ian Dixon on the LEAP Technology, Exopharm has built a highly skilled team with broad manufacturing, scientific and commercial expertise. Our success would not be possible without the exceptional minds working together behind the scenes with a range of capabilities across specialised areas.